The EIF5A2 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line, in which the EIF5A2 gene has been disrupted to generate a loss-of-function model. This polyclonal population, derived from pooled gene-edited cells, provides a genetically heterogeneous tool for investigating EIF5A2 function. The target-gene disruption is achieved through CRISPR/Cas9-mediated genome editing, enabling robust abrogation of EIF5A2 expression without single-cell cloning.
HT29 cells, isolated from a primary colon adenocarcinoma of a 44-year-old female, are a well-established colonic epithelial tumor model characterized by their ability to undergo enterocytic differentiation and produce mucin under appropriate conditions. These cells exhibit stable, adherent growth and are extensively used in colorectal cancer research, particularly for studies on differentiation pathways, drug response, and signal transduction. Their epithelial features and moderate tumorigenicity in vivo make them an ideal host to examine the role of oncogenic factors like EIF5A2 in colon tumor biology.
EIF5A2 encodes a eukaryotic translation elongation factor that undergoes hypusination, a unique modification catalyzed by deoxyhypusine synthase (DHPS) and deoxyhypusine hydroxylase (DOHH). Hypusination, regulated by mTORC1-S6K1 signaling, enables EIF5A2 to facilitate ribosomal translation of polyproline-rich motifs in proteins driving cell cycle, survival, and motility. Upstream regulators c-Myc and HIFs transcriptionally activate EIF5A2, while downstream targets include cyclin D1, MMP2, MMP9, and Bcl-xL. EIF5A2 also interacts with exportin-T and translation machinery, forming a critical node linking nutrient-sensing mTOR signals to oncogenic programs.
In the HT29 colorectal cancer context, EIF5A2 is frequently overexpressed and contributes to aggressive tumor behavior by enhancing proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT). Knockout of EIF5A2 in this background is expected to diminish the synthesis of polyproline-containing proteins that drive these malignant phenotypes, thereby attenuating the tumorigenic potential of the cells. This model thus provides a physiologically relevant system to dissect the mTOR-hypusination axis and its role in colorectal cancer progression, as well as to evaluate potential therapeutic strategies targeting this pathway.
Researchers can use these EIF5A2 knockout HT29 polyclonal cells in functional assays such as western blotting and RT-qPCR to confirm knockout and assess downstream signaling, MTT or BrdU proliferation assays to measure growth deficits, Transwell migration and invasion assays to quantify metastatic capacity, and Annexin V apoptosis assays to evaluate cell death sensitivity. The cells are also suitable for polyproline-luciferase translation reporter assays to monitor EIF5A2-dependent translation and co-immunoprecipitation studies to probe protein interactions. Applications include studying EIF5A2??s role in mTOR-driven colorectal cancer, screening for EIF5A2 inhibitors, and investigating EMT and metastasis mechanisms. For further details or technical support, please contact Ascent Research.
